

London, 27 July 2006 Doc. Ref. EMEA/CHMP/SWP/194898/2006

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CHMP)

DRAFT

GUIDELINE ON CARCINOGENICITY EVALUATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV INFECTION

DRAFT AGREED BY SAFETY WORKING PARTY	May 2006
ADOPTION BY CHMP FOR RELEASE FOR CONSULTATION	27 July 2006
END OF CONSULTATION (DEADLINE FOR COMMENTS)	31 January 2007

Comments should be provided using this <u>template</u> to <u>EMEA-H.SWP@emea.eu.int</u> Fax +44 20 7418 8613

KEYWORDS Carcinogenicity, genotoxic, HIV (Human Immunodeficiency Virus)

GUIDELINE ON CARCINOGENICITY EVALUATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV INFECTION

TABLE OF CONTENTS

1	INT	RODUCTION	. 3
2	SCC)PE	. 3
3	LEG	AL BASIS	. 4
4	GEN	VERAL CONSIDERATIONS	. 4
5	TIM	ING OF THE EVALUATION OF CARCINOGENICITY	. 4
	5.1	Carcinogenicity	.4
	5.2	Combination of anti-HIV Products	. 5
	5.3	Paediatric use	. 5
	5.4	Use in pregnant women	. 5
6	NON	N-CLINICAL DATA IN THE SPC	. 5
7	GLC	DSSARY AND ABBREVIATIONS	. 7
8	REF	ERENCES	. 8

EXECUTIVE SUMMARY

Different classes of medicinal products for the treatment of the Human Immunodeficiency Virus (HIV-1) infection have been and continue to be developed. Some classes have shown equivocal genotoxic properties while others have been shown to be clearly genotoxic, and nearly all products were found to induce tumours in rodents. The benefit of treatment of HIV-infected patients has so far outweighed the risk of carcinogenicity because of their short life expectancy. Life expectancy of HIV-infected patients has increased significantly since these medicinal products were first introduced. Therefore, the potential carcinogenic risk posed by the available products is being reconsidered. It is generally expected that the results of the carcinogenicity studies are submitted before granting a marketing authorisation. However, for products intended for the treatment of patients with limited treatment options or of a clearly demonstrable added value, the submission of the results of the carcinogenicity studies as a post-approval commitment may be accepted. The need for carcinogenicity testing should be addressed prior to long term exposure in paediatric clinical trials considering the length of treatment or cause for concern.

1 INTRODUCTION

Different classes of medicinal products for the treatment of the Human Immunodeficiency Virus (HIV-1) infection, with different modes of action and toxic profiles have been and continue to be developed. Current options for anti-retroviral therapy (ART) for the treatment of HIV-1 infection consist of four classes of compounds: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs), protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and fusion inhibitors (FIs). Due to the inherent high mutation rate in HIV, the combined use of at least three active medicinal products, so called Highly Active Anti-retroviral Therapy (HAART), is currently considered to be essential and the standard of care of HIV-1 infected patients. The choice of the combination regimens depends on the status of the patient, particularly in terms of plasma viral load (HIV RNA), CD4 cell counts, previous treatment(s), prior relapse and intolerance to treatment.

Some classes of these anti-retroviral agents have shown equivocal genotoxic properties while others have been shown to be clearly genotoxic. Nearly all products have exhibited positive findings in the available two-year rodent carcinogenicity studies. The benefit of treatment of HIV-infected patients has so far outweighed the risk of carcinogenicity because of their short life expectancy. Life expectancy of HIV-infected patients has increased significantly since these medicinal products were first introduced. Available clinical data provide evidence that the development of HAART has reduced the incidence of the majority of HIV-associated tumours and has generally improved their responsiveness to therapy (Mayor et al.2005, Yarchoan et al.2005). Nevertheless, the potential carcinogenic risk posed by the available products is being reconsidered.

The development of this Guideline is a consequence of recent advances in scientific knowledge in this field, and sets out some of the requirements expected by regulators.

2 SCOPE

The present Guideline mainly applies to the development of new medicinal products for the treatment of HIV infection.

The main objective of this guideline is to define the timing of and conditions under which genotoxicity and carcinogenicity studies should be conducted during development and before authorisation for any new anti-HIV Medicinal Product.

In addition, it will provide recommendations for describing this non-clinical information in the SPC (section 5.3 Preclinical safety data).

3 LEGAL BASIS

This document should be read in conjunction with Directive 2001/83/EC (as amended) and all relevant CHMP and ICH Guidelines.

This document is meant as guidance only. Deviations from guidance should be justified and, seeking European regulatory scientific advice is recommended, especially when compounds belonging to new classes of ART are under development.

CHMP and ICH Guidance documents that are especially important are listed under 'References' (Section 8).

4 GENERAL CONSIDERATIONS

As mentioned previously, some classes of these anti-retroviral agents have shown equivocal genotoxic properties while others have shown to be clearly genotoxic, and nearly all agents have exhibited positive findings in the available two-year rodent carcinogenicity studies. Also, there is evidence that additive or synergistic mutagenic effects correlate with additive or synergistic antiviral effects of these drug combinations (Meng et al. 2000 Therefore, the weight of the carcinogenic risk posed by the available agents may need to be reconsidered.

The ICH Guidance on the Need for Carcinogenicity Studies of Pharmaceuticals defines the circumstances when carcinogenicity studies are required (CPMP/ICH/140/95). This Guideline states that carcinogenicity studies should be performed for any medicinal product whose expected clinical use is continuous for at least 6 months. In general, when carcinogenicity studies are required, they usually need to be completed pre-authorisation except for pharmaceuticals developed to treat certain serious diseases, as it is the case of Acquired Immune-deficiency Syndrome (AIDS) where no satisfactory alternative therapy exists.

When these anti-HIV medicinal products were first introduced during the last decades, the lifeexpectancy of HIV patients was limited and the potential risk of a carcinogenic effect was considered of low relevance. Today, life expectancy of HIV-infected patients has increased significantly and thus HIV infection is considered to be a chronic condition. Therefore, the need and timing of carcinogenicity studies in the development of anti-HIV drugs is now being reconsidered in the overall benefit/risk evaluation of these products, as compounds with less risk might be available.

5 TIMING OF THE EVALUATION OF CARCINOGENICITY

5.1 Carcinogenicity

Considering on one hand the chronic course of the HIV infection among treated patients and their life expectancy, and on the other hand that nearly all antiretroviral agents have exhibited positive findings in the available two-year rodent carcinogenicity studies (but not all are relevant to humans, especially liver tumours induced by NNRTIs), it is in principle expected that, as for any product for which the expected clinical use is continuous for at least 6 months, the results of carcinogenicity studies are submitted before granting the marketing authorisation. However, according to the Note for Guidance on The need for Carcinogenicity Studies of Pharmaceuticals (CPMP/ICH/140/95), for products intended for the treatment of patients with limited treatment options or of a clearly demonstrable added value, the submission of the results of the carcinogenicity studies as a post-approval commitment may be accepted. European regulatory scientific advice is recommended, especially when compounds belonging to new classes of ART are under development.

In case of positive findings in the results of carcinogenicity studies conducted, Companies are required to provide mechanistic data to support the possible explanations of the tumour findings that would help to clarify the clinical relevance.

5.2 Combination of anti-HIV Products

Carcinogenicity studies of HIV drug combinations are usually not needed if the individual components have been adequately tested. In case of positive findings with the individual compounds, additive effects when tested in combination can be expected (and estimated without further testing) and should provide the basis for hazard evaluation. Deviations from this approach might be needed if knowledge of possible are available suggesting a potential to synergistically enhance adverse effects not detectable from the data profile of the individual compounds.

5.3 Paediatric use

The standard battery of genotoxicity tests should be completed prior to the initiation of clinical trials in paediatric populations with new anti-HIV products. The need for carcinogenicity testing should be addressed prior to long term exposure in paediatric clinical trials considering the length of treatment (or cause for concern) (CPMP/ICH/286/95).

5.4 Use in pregnant women

The need to further optimise anti-retroviral therapy in pregnant women is fully recognised, balancing the risk of sub-optimal therapy, viral resistance and vertical viral transmission against foetal toxicity and long-term consequences for the child. Currently, HAART combinations are highly effective in preventing HIV-1 vertical transmission. However, some of the anti-HIV agents are strong transplacental carcinogens in animal species. Also, transplacental genotoxicity enhancement has been reported for combined antiretroviral nucleoside analogue therapy in animal species (Olivero OA et al., 2002), and the potential long-term consequences of foetal exposure to most HAART combinations remain unknown.

Carcinogenicity studies should be completed before marketing authorisation submission if it is possible that the new product may be used in pregnant women. For products intended for the treatment of pregnant women with limited treatment options or of clearly demonstrable added value, the submission of the results of the carcinogenicity studies as a post-approval commitment may be accepted.

It should be considered that as the use of new products during pregnancy is inevitable, the applicants should commit to provide reliable follow-up data of children exposed *in-utero* to anti-retroviral compounds at least until a reasonably founded benefit risk assessment is achievable. This should include long-term follow-up as far as possible as regards potential carcinogenic effects (CPMP/EWP/633/02).

The standard battery of genotoxicity tests should be conducted prior to the inclusion of pregnant women in clinical trials with new anti-HIV agents.

6 NON-CLINICAL DATA IN THE SPC

In the Summary of Products Characteristics (SPC), section 5.3 (Preclinical safety data), adequate information should be given on any findings in the genotoxicity and carcinogenicity studies which could be of relevance for the prescriber in recognising the genotoxic and carcinogenic potential of anti HIV products.

Any genotoxic and carcinogenic positive finding should be indicated in relation to the maximal expected human exposure at the recommended therapeutic doses.

In case of tumour findings in the carcinogenicity studies, the mechanism of tumour formation and the potential clinical relevance should be stated.

Statement examples and recommendations given in the Guideline on Summary of Products Characteristics (CHMP/64302/2005) should be followed particularly when positive genotoxic and carcinogenic findings are reported and should be mentioned in the SPC. It is recommended that too much detail is not given in relation to the specific aspects of the studies conducted. The studies should be described in brief and qualitative statements as outlined in the following example statements:

Mutagenicity:

- [Active substance] was not mutagenic or clastogenic in conventional genotoxicity assays.
- [Active substance] was or was not genotoxic *in vivo* at doses that gave plasma concentrations e.g. around. 20-fold (in round figures) the anticipated clinical plasma levels.
- [Active substance] was genotoxic in *in vitro* tests.

(not exhaustive list of possibilities)

Carcinogenicity:

- Carcinogenicity studies of [Active substance] in mice and rats did not show any carcinogenic potential.
- Carcinogenicity studies of [Active Substance] in mice and rats revealed tumourigenic potential specific for these species, which are regarded as of no clinical relevance.
- Carcinogenicity studies of [Active Substance] in mice and rats revealed tumourigenic potential specific for these species, but their clinical significance is unknown.
- [Active substance] was carcinogenic in animal species (organ tumours) at high exposure levels. No carcinogenicity was noted at doses corresponding to exposures (rough estimate) times the expected human exposure, respectively, suggesting an insignificant carcinogenic potential of [Active Substance] in clinical therapy.
- Carcinogenicity studies showed an increased incidence in (organ tumour) in (animal species). The mechanism of tumour formation and the potential clinical relevance is not known. Carcinogenicity studies in (animal species) were negative. While the carcinogenic potential is unknown, these data suggest that the clinical benefit of [Active substance] outweighs the potential carcinogenic risk to humans.

7 GLOSSARY AND ABBREVIATIONS

AIDS	Acquired immune-deficiency syndrome
ART	Anti-retroviral therapy, currently consisting of at least 3 different compounds (frequently from 2 different substance classes)
FDC	Fixed Dose Combinations
HAART =ART	Highly Active Anti-retroviral Therapy
HIV	Human immunodeficiency virus
NNRTI	Non-nucleoside reverse transcriptase inhibitor
NRTI	Nucleoside reverse transcriptase nhibitor
PI	Protease inhibitor
FI	Fusion inhibitor

8 **REFERENCES**

- Note for Guidance on Carcinogenic Potential (CPMP/SWP/2877/00)
- Note for Guidance on the Need For Carcinogenicity Studies of Pharmaceuticals (CPMP/ICH/140/95)
- Note for Guidance on Carcinogenicity Testing for Carcinogenicity of Pharmaceuticals (CPMP/ICH/299/95)
- Note for Guidance on Dose Selection for Carcinogenicity Studies of Pharmaceuticals (CPMP/ICH/383/95)
- Note for Guidance on Addition of a Limited Dose and Related Notes (CPMP/ICH/366/96)
- Conclusions and Recommendations of Use of Genetically modified animal models for carcinogenicity assessment (CPMP/SWP/2592/02).
- Note for Guidance on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals (CPMP/ICH/286/95)
- Guidance on specific aspects of regulatory genotoxicity test (CPMP/ICH/141/95)
- Note for Guidance on Genotoxicity: a Standard Battery for genotoxicity testing of pharmaceuticals ((CPMP/ICH/174/95)
- Mayor AM, Gomez MA, Rios-Oliveras E, Hunter-Mellado RF. Mortality trends of HIVinfected patients after the introduction of higly active antiretroviral therapy: analysis of a cohort of 3,322 HIV-infected persons. Eth Dis. 2005 Autumn; 15(4 Suppl 5): S5-57-62.
- Meng, Q, Walker D.M., Olivero O.A., Shi, X., Antiochos B.B., Poirier, M.C., Walker V.E. Zidovudine-didanosine co-exposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proceedings of the National Academy of Sciences of the United States of America: vol 97, No 23, 12667-12671, November 2000
- Olivero, OA, Fernandez, J.J., Antiochos, B.B., Wagner J.L., St. Claire, M.E., Poirier M.C. Transplacental Genotoxicity of Combined Antiretroviral Nucleoside Analogue Therapy in *Erythrocebus patas* Monkeys. Journal of Acquired Immune Deficiency Syndromes.No29: 323-329, 2002.
- Yarchoan R, Toasto G, Little RF. Therapy Insight: AIDS-related malignancies the influence of antiviral therapy on pathogenesis and management. Nature Clinical Practice Oncology 2005; 2(8): 406-415.
- Guideline on Clinical Evaluation of Medicinal Products for the treatment of HIV infection. (CPMP/EWP/633/02).